Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in adult subjects with type 2 diabetes mellitus: a long-term, outpatient, open-label, parallel-group comparative trial.

Trial Profile

Efficacy and safety of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in adult subjects with type 2 diabetes mellitus: a long-term, outpatient, open-label, parallel-group comparative trial.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions

Most Recent Events

  • 21 Jul 2008 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
  • 03 Jan 2008 The expected completion date for this trial is now 1 Mar 2010.
  • 03 Jan 2008 Status change from in progress to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top